scholarly journals Silencing of SARS‐CoV‐2 with modified siRNA‐peptide dendrimer formulation

Allergy ◽  
2021 ◽  
Author(s):  
Musa Khaitov ◽  
Alexandra Nikonova ◽  
Igor Shilovskiy ◽  
Ksenia Kozhikhova ◽  
Ilya Kofiadi ◽  
...  
Keyword(s):  

2016 ◽  
Vol 1858 (12) ◽  
pp. 3005-3016 ◽  
Author(s):  
Sophie Melikishvili ◽  
Alexandra Poturnayova ◽  
Maksim Ionov ◽  
Maria Bryszewska ◽  
Tomáš Vary ◽  
...  


Pharmaceutics ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1092
Author(s):  
Dandan Zhu ◽  
Huanle Zhang ◽  
Yuanzheng Huang ◽  
Baoping Lian ◽  
Chi Ma ◽  
...  

Despite being a mainstay of clinical cancer treatment, chemotherapy is limited by its severe side effects and inherent or acquired drug resistance. Nanotechnology-based drug-delivery systems are widely expected to bring new hope for cancer therapy. These systems exploit the ability of nanomaterials to accumulate and deliver anticancer drugs at the tumor site via the enhanced permeability and retention effect. Here, we established a novel drug-delivery nanosystem based on amphiphilic peptide dendrimers (AmPDs) composed of a hydrophobic alkyl chain and a hydrophilic polylysine dendron with different generations (AmPD KK2 and AmPD KK2K4). These AmPDs assembled into nanoassemblies for efficient encapsulation of the anti-cancer drug doxorubicin (DOX). The AmPDs/DOX nanoformulations improved the intracellular uptake and accumulation of DOX in drug-resistant breast cancer cells and increased permeation in 3D multicellular tumor spheroids in comparison with free DOX. Thus, they exerted effective anticancer activity while circumventing drug resistance in 2D and 3D breast cancer models. Interestingly, AmPD KK2 bearing a smaller peptide dendron encapsulated DOX to form more stable nanoparticles than AmPD KK2K4 bearing a larger peptide dendron, resulting in better cellular uptake, penetration, and anti-proliferative activity. This may be because AmPD KK2 maintains a better balance between hydrophobicity and hydrophilicity to achieve optimal self-assembly, thereby facilitating more stable drug encapsulation and efficient drug release. Together, our study provides a promising perspective on the design of the safe and efficient cancer drug-delivery nanosystems based on the self-assembling amphiphilic peptide dendrimer.



2018 ◽  
Vol 132 ◽  
pp. 29-40 ◽  
Author(s):  
Osama Saher ◽  
Cristina S.J. Rocha ◽  
Eman M. Zaghloul ◽  
Oscar P.B. Wiklander ◽  
Susanna Zamolo ◽  
...  


2018 ◽  
Vol 6 (3) ◽  
pp. 604-613 ◽  
Author(s):  
Fu-Hua Liu ◽  
Chun-Yuan Hou ◽  
Di Zhang ◽  
Wen-Jing Zhao ◽  
Yong Cong ◽  
...  

Cytotoxic peptide conjugated PAMAM dendrimers with MMP2-sensitive PEG for efficient tumor penetration, cellular internalization and mitochondria disruption.



Pharmaceutics ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 666
Author(s):  
Osama Saher ◽  
Taavi Lehto ◽  
Olof Gissberg ◽  
Dhanu Gupta ◽  
Oskar Gustafsson ◽  
...  

Non-viral transfection vectors are commonly used for oligonucleotide (ON) delivery but face many challenges before reaching the desired compartments inside cells. With the support of additional compounds, it might be more feasible for a vector to endure the barriers and achieve efficient delivery. In this report, we screened 18 different excipients and evaluated their effect on the performance of peptide dendrimer/lipid vector to deliver single-stranded, splice-switching ONs under serum conditions. Transfection efficiency was monitored in four different reporter cell lines by measuring splice-switching activity on RNA and protein levels. All reporter cell lines used had a mutated human β-globin intron 2 sequence interrupting the luciferase gene, which led to an aberrant splicing of luciferase pre-mRNA and subsidence of luciferase protein translation. In the HeLa Luc/705 reporter cell line (a cervical cancer cell line), the lead excipients (Polyvinyl derivatives) potentiated the splice-switching activity up to 95-fold, compared to untreated cells with no detected cytotoxicity. Physical characterization revealed that lead excipients decreased the particle size and the zeta potential of the formulations. In vivo biodistribution studies emphasized the influence of formulations as well as the type of excipients on biodistribution profiles of the ON. Subsequently, we suggest that the highlighted impact of tested excipients would potentially assist in formulation development to deliver ON therapeutics in pre-clinical and clinical settings.



2009 ◽  
Vol 113 (50) ◽  
pp. 16268-16275 ◽  
Author(s):  
D. Moiani ◽  
M. Salvalaglio ◽  
C. Cavallotti ◽  
A. Bujacz ◽  
I. Redzynia ◽  
...  


ACS Nano ◽  
2013 ◽  
Vol 7 (5) ◽  
pp. 4668-4682 ◽  
Author(s):  
Albert Kwok ◽  
Gabriela A. Eggimann ◽  
Jean-Louis Reymond ◽  
Tamis Darbre ◽  
Florian Hollfelder


Molecules ◽  
2017 ◽  
Vol 22 (12) ◽  
pp. 2088 ◽  
Author(s):  
Chi-on Chan ◽  
Jing Jing ◽  
Wei Xiao ◽  
Zhexu Tan ◽  
Qiuyue Lv ◽  
...  


2021 ◽  
Author(s):  
Dina Erzina ◽  
Alice Capecchi ◽  
Sacha Javor ◽  
Jean-Louis Reymond


2021 ◽  
pp. 119025
Author(s):  
Viorica Patrulea ◽  
Bee-Ha Gan ◽  
Karl Perron ◽  
Xingguang Cai ◽  
Philippe Abdel-Sayed ◽  
...  


Sign in / Sign up

Export Citation Format

Share Document